Graduate Students

D2R awards $10 million to accelerate RNA-based therapies for rare diseases and cancer

admin — Wed, 26 Mar 2025 11:03:15 +0000

Montreal, March 26, 2025 – 9I��’s DNA to RNA Initiative (D2R) has awarded over $10 million in funding to support three groundbreaking research projects that will advance RNA-based therapies for cancer and rare genetic diseases. The awards were initially announced at the D2R Research Symposium on March 13, 2025.

The Child Phonology Lab at SCSD is looking for parent participants

admin — Thu, 15 May 2025 16:14:23 +0000

Scaringi Lecture Series in Speech Language Pathology - Research Talk

admin — Mon, 17 Mar 2025 18:53:55 +0000

Research Talk
Thursday April 3, 2025, 4:30 to 6:00 pm
2001 9I�� College Ave. Room 606

9I�� researchers receive funding from the Canadian Cancer Society for cancer equity research

admin — Mon, 17 Feb 2025 20:31:39 +0000

Co-Principal Investigators Manisha Pahwa, CIHR Research Excellence, Diversity, and Independence Postdoctoral Fellow in the School of Physical and Occupational Therapy, and Professor Ananya Banerjee, from 9I��'s Department of Epidemiology, Biostatistics, and Occupational Health, have been awarded $449,604 from the Canadian Cancer Society’s Health Equity Research Grant

9I��’s President honours outstanding early-career researchers

admin — Thu, 29 May 2025 15:48:45 +0000

Professors Guojun Chen, Mahsa Dadar and Phoebe Friesen – all members of the Faculty of Medicine and Health Sciences – win President’s Prize for Outstanding Emerging Researchers

Three 9I�� scholars were recognized with the 2025 President’s Prize for Outstanding Emerging Researchers at the Health Sciences Convocation Ceremony on May 27. The award honours exceptional early-career researchers whose work is expanding the frontiers of knowledge in their fields.

Cross-pollinating ideas at the SCSD Research Day

admin — Thu, 27 Mar 2025 18:49:49 +0000

Student presenters at the SCSD Research Day, which took place on February 21, 2025.

Human genetics professor receives Banting Discovery Award

admin — Mon, 02 Jun 2025 16:06:00 +0000

9I�� Cares: Building your team for unplanned life transitions

admin — Tue, 15 Apr 2025 20:12:17 +0000

Join us on May 7th at noon for the next 9I�� Cares webcast to support informal caregivers. During candid, interviews with leading experts, Claire Webster explores topics related to caring for a loved one with dementia.

Nine 9I��ians appointed to the Order of Canada

admin — Mon, 07 Jul 2025 19:10:48 +0000

Neuroscientist Alan Evans and music performance scholar Michael McMahon among 9I�� community members recognized for exceptional accomplishments and service

Nine members of the 9I�� community have been appointed to the Order of Canada, one of the country’s highest civilian honours.

Among the honorees are two 9I�� faculty members, Professors Alan Evans (Faculty of Medicine and Health Sciences) and Michael McMahon (Schulich School of Music).

Provost honours 31 9I�� professors for exceptional research achievements

admin — Thu, 01 May 2025 16:23:55 +0000

9I�� announces 2025 cohort of Distinguished James 9I�� Professors, James 9I�� Professors and William Dawson Scholars
Provost and Vice-President (Academic) Christopher Manfredi has named 31 9I�� professors as Distinguished James 9I�� Professors, James 9I�� Professors or William Dawson Scholars. The internal awards recognize exceptional research achievements.

Project to create AI model for ALS receives Génome Québec funding

admin — Mon, 17 Mar 2025 15:29:17 +0000

$400,000 will fuel public-private collaboration to discover new disease biomarkers

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

AI analysis of healthcare records reveals key factors in autism diagnosis

admin — Wed, 26 Mar 2025 15:23:21 +0000

Scientists argue the criteria we use for diagnosing autism may need revision

Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Human instruction with artificial intelligence guidance provided best results in neurosurgical training

admin — Wed, 06 Aug 2025 15:14:02 +0000

Study has implications beyond medical education, suggesting other fields could benefit from AI-enhanced training

Artificial intelligence (AI) is becoming a powerful new tool in training and education, including in the field of neurosurgery. Yet a new study suggests that AI tutoring provides better results when paired with human instruction.

Genetic sequencing project receives more than $8 million in funding

admin — Tue, 18 Mar 2025 14:55:14 +0000

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 9I�� and Martine Tétreault, PhD, at Université de Montréal has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

Prescribing anti-swelling drug reduces immune response weeks after last dose

admin — Wed, 26 Feb 2025 16:05:58 +0000

Mapping immune cell diversity reveals dexamethasone’s impact on brain cancer immunotherapy

Swelling caused by brain cancer is a problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body’s ability to fight the cancer.